Search results for "autoimmune"

showing 8 items of 648 documents

Decreasing muscle performance associated with increasing disease activity in patients with rheumatoid arthritis

2018

Objectives Increasing evidence suggests that inflammation has a detrimental effect on muscle strength. Our objective was to analyse the association between muscle performance and different disease activity levels in patients with rheumatoid arthritis (RA). Method A total of 199 consecutive outpatients were subject to cross-sectional assessment. Measurements of grip strength, endurance of the upper and lower limbs and trunk strength were combined as a muscle performance composite score (MPCS), using a standardised method. The disease activity for 28 joints (DAS28), radiographs of small joints (Larsen score), rheumatoid factor, body mass index (BMI), comorbidities and anti-rheumatic drugs wer…

nivelreumarheumatoid arthritisMaleINACTIVITYArthritislcsh:MedicineMuscle ProteinsComorbidityBiochemistrySeverity of Illness IndexArthritis RheumatoidGrip strength0302 clinical medicineRisk FactorsSTRENGTHCACHEXIAMedicine and Health SciencesCRITERIAPublic and Occupational Health030212 general & internal medicinelcsh:ScienceMusculoskeletal SystemINDEXPain Measurement2. Zero hungerMultidisciplinaryMusclesWOMENta3141Muscle AnalysisMiddle AgedSports Science3. Good healthBioassays and Physiological AnalysisRheumatoid arthritisStrength TrainingFemaleBONE-MINERAL DENSITYAnatomylihaskuntoResearch Articlemedicine.medical_specialtymuscle fitnessStrength trainingHEALTHY CONTROLSImmunologyRheumatoid ArthritisResearch and Analysis MethodsAutoimmune Diseases03 medical and health sciencesRheumatologyInternal medicineHand strengthmedicineRheumatoid factorHumansMuscle StrengthRisk factorSports and Exercise MedicineMuscle SkeletalExercise030203 arthritis & rheumatologybusiness.industryArthritislcsh:RENERGY-EXPENDITUREBeck Depression InventoryBiology and Life SciencesProteinsPhysical Activitymedicine.diseaseJoints (Anatomy)PHYSICAL-ACTIVITYCross-Sectional StudiesSkeletal MusclesPhysical Fitness3121 General medicine internal medicine and other clinical medicinemuscle strengthPhysical Endurancelcsh:QClinical ImmunologyClinical MedicinebusinesslihasvoimaPLoS ONE
researchProduct

Pepsinogēna un gastrīna-17 nozīme autoimūna gastrīta diagnostikā

2015

Ievads: AG ir pārāk reti diagnosticēts stāvoklis ar augstu KV attīstības risku. Ilgstošas asimptomātiskas gaitas dēļ to ir grūti diagnosticēt, tāpēc nepieciešamas jaunas, efektīvas un mazāk invazīvas diagnostikas metodes. Mērķis: Darba mērķis ir analizēt seruma biomarķieru (pepsinogēns, G-17) nozīmīgumu AG diagnostikā. Materiāli un metodes: Pētījuma modelis ir nejaušās izlases princips, iekļaujot pacientus, kuri laika periodā no 2004. - 2014. gadam Gremošanas veikuši augšējā gastrointenstinālā trakta endoskopiju. Lai izmērītu seruma biomarķieru (pepsinogēns un G-17) līmeni, pacientiem tika ņemti asins paraugi. Balstoties uz Sidnejas klasifikāciju, tika ņemtas biopsijas. Rezultāti: Pētījumā …

non-atrophic(NA)Total atrophy(TA)Pepsinogen I/II ratio(PI/II)Autoimmune gastritis(AG)MedicīnaAntral atrophy(AA)
researchProduct

L'ESAME CAPILLAROSCOPICO ORALE: NUOVA METODICA DIAGNOSTICA

2005

The morphological-functional study of microcirculation is of fundamental importance; in fact, the microvascular bed is directly involved both in autoimmune etiopathogenesis pathologies, and in acute and chronic inflammatory etiopathogenesis pathologies. Oral capillaroscopy is a very stimulating method for studying microcirculation, because of the possibility of studying small vessels in vivo by means of a microscope. Today, it is becoming more reliable thanks to the improvement of the observation tools (photography, videomicroscopy).

postnatal hypothyroidismHypothyroidismMouth Diseases/pathologySettore MED/28 - Malattie OdontostomatologicheMicrocirculationCongenital HypothyroidismAutoimmune Diseases/pathologyMicroscopic Angioscopy/method
researchProduct

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.

2021

The past decades have yielded major therapeutic advances in many autoimmune conditions – such as multiple sclerosis (MS) – and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy much more challenging for the attending physician, especially when treating patients with more than one autoimmune condition. Importantly, some therapeutic strategies are either approved for several autoimmune disorders or may be repurposed for other conditions, therefore opening new curative possibilities in related fields. In this article, we especially focus on frequent and therapeutically rele…

rheumatoid arthritismedicine.medical_specialtymedicine.medical_treatmentPsychological interventionReviewmultiple sclerosisInflammatory bowel diseaseinflammatory bowel diseasePsoriasismedicineRC346-429Intensive care medicinePharmacologybusiness.industryMultiple sclerosisInflammatory Bowel DiseasesImmunotherapypsoriasismedicine.diseaseNeurologyRheumatoid arthritisNeurology. Diseases of the nervous systemNeurology (clinical)immunotherapyAutoimmune conditionbusinessTherapeutic advances in neurological disorders
researchProduct

Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases.

2022

Vitamin D is a steroid hormone regulating calcium-phosphorus homeostasis, immune response and brain function. In the past thirty years, an increasing number of cohort studies, meta-analyses and randomized controlled trials (RTCs) evaluated the serum levels of 25-hydroxyvitamin D [25(OH)D], which is considered the Vitamin D status biomarker, in patients affected by neurological, psychiatric and autoimmune diseases. Although an association between low 25(OH)D serum levels and the prevalence of these diseases has been found, it is still unclear whether the serum 25(OH)D measurement can be clinically useful as a biomarker for diagnosis, prognosis and predicting treatment response in neurodegene…

standardizationMedicine (General)25(OH)DClinical Biochemistrypsychiatric diseasesvitamin DReviewmultiple sclerosisR5-920Settore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicabiomarkerautoimmune diseasesneurodegenerative diseasesAlzheimer’s diseaseDiagnostics (Basel, Switzerland)
researchProduct

Clinicopathological analysis of oral mucous autoimmune disease : a 27-year study

2008

Made available in DSpace on 2022-04-28T20:39:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-02-01 Objectives: The aim of the present study was to analyze the main clinical and histopathological features of autoimmune diseases with oral manifestations such as oral lichen planus (OLP); mucous membrane pemphigoid (MMP); pemphigus vulgaris (PV) and erythema multiforme (EM). Study design: Retrospective review of 5770 files from the Oral Pathology Laboratory of São José dos Campos Dental School, São Paulo State University (UNESP) comprising a 27-year period from 1974 to 2000. Results: The cases accounted for 64 (1.10%) of 5770 anatomopathological examinations performed over the study p…

stomatognathic diseasesErythema multiformeAutoimmune diseasesUNESCO::CIENCIAS MÉDICASMucous membraneLichen planus:CIENCIAS MÉDICAS [UNESCO]PemphigoidPemphigus
researchProduct

Metabolic Reprogramming of Innate Immune Cells as a Possible Source of New Therapeutic Approaches in Autoimmunity.

2022

Immune cells undergo different metabolic pathways or immunometabolisms to interact with various antigens. Immunometabolism links immunological and metabolic processes and is critical for innate and adaptive immunity. Although metabolic reprogramming is necessary for cell differentiation and proliferation, it may mediate the imbalance of immune homeostasis, leading to the pathogenesis and development of some diseases, such as autoimmune diseases. Here, we discuss the effects of metabolic changes in autoimmune diseases, exerted by the leading actors of innate immunity, and their role in autoimmunity pathogenesis, suggesting many immunotherapeutic approaches.

therapyoxidative phosphorylationchronic inflammatory diseaseAutoimmunityGeneral MedicineglycolysisAdaptive Immunityimmune responseImmunity InnateAutoimmune Diseasesmetabolic pathwaysHumansinnate immunityMetabolic Networks and PathwaysCells
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct